Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

Avicanna Inc

0NN:STU

Avicanna Inc

Actions
  • Price (--)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
--
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Avicanna Inc. is a Canada-based commercial-stage international biopharmaceutical company. The Company's scientific platform commercializes over thirty products across various market segments: Medical Cannabis formulary (RHO Phyto), Medical cannabis care platform (MyMedi.ca), Pharmaceutical pipeline, and Active pharmaceutical ingredients (Aureus Santa Marta). RHO Phyto formulary offers a diverse range of proprietary products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca is a medical cannabis care platform and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. Aureus Santa Mart is a commercial-stage business providing a various forms CBD, THC and CBG to the Company's international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products.

  • Revenue in CAD (TTM)24.87m
  • Net income in CAD-7.44m
  • Incorporated2016
  • Employees38.00
  • Location
    Avicanna Inc480 UNIVERSITY AVENUE, SUITE 1502TORONTO M5G 1V2CanadaCAN
  • Phone+1 (647) 243-5283
  • Fax+1 (647) 243-5283
  • Websitehttps://avicanna.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.